Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study

English version České info

Background:
Some evidence suggests that proton pump inhibitors (PPIs) are an under-appreciated risk factor for hypomagnesemia. Whether hospitalization with hypomagnesemia is associated with use of PPIs is unknown.

Methods and Findings:
We conducted a population-based case-control study of multiple health care databases in Ontario, Canada, from April 2002 to March 2012. Patients who were enrolled as cases were Ontarians aged 66 years or older hospitalized with hypomagnesemia. For each individual enrolled as a case, we identified up to four individuals as controls matched on age, sex, kidney disease, and use of various diuretic classes. Exposure to PPIs was categorized according to the most proximate prescription prior to the index date as current (within 90 days), recent (within 91 to 180 days), or remote (within 181 to 365 days). We used conditional logistic regression to estimate the odds ratio for the association of outpatient PPI use and hospitalization with hypomagnesemia. To test the specificity of our findings we examined use of histamine H2 receptor antagonists, drugs with no causal link to hypomagnesemia. We studied 366 patients hospitalized with hypomagnesemia and 1,464 matched controls. Current PPI use was associated with a 43% increased risk of hypomagnesemia (adjusted odds ratio, 1.43; 95% CI 1.06–1.93). In a stratified analysis, the risk was particularly increased among patients receiving diuretics, (adjusted odds ratio, 1.73; 95% CI 1.11–2.70) and not significant among patients not receiving diuretics (adjusted odds ratio, 1.25; 95% CI 0.81–1.91). We estimate that one excess hospitalization with hypomagnesemia will occur among 76,591 outpatients treated with a PPI for 90 days. Hospitalization with hypomagnesemia was not associated with the use of histamine H2 receptor antagonists (adjusted odds ratio 1.06; 95% CI 0.54–2.06). Limitations of this study include a lack of access to serum magnesium levels, uncertainty regarding diagnostic coding of hypomagnesemia, and generalizability of our findings to younger patients.

Conclusions:
PPIs are associated with a small increased risk of hospitalization with hypomagnesemia among patients also receiving diuretics. Physicians should be aware of this association, particularly for patients with hypomagnesemia.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study. PLoS Med 11(9): e32767. doi:10.1371/journal.pmed.1001736
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001736

Souhrn

Zdroje

1. IMS Institute for Healthcare Informatics (2011) The Use of Medicine in the United States: Review of 2010. Available: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20File/IHII_UseOfMed_report.pdf. Accessed 10 April 2014.

2. RichardsonP, HawkeyCJ, StackWA (1998) Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 56: 307–335.

3. SalasM, WardA, CaroJ (2002) Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol 2: 17.

4. PoynardT, LemaireM, AgostiniH (1995) Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 7: 661–665.

5. LeonardJ, MarshallJK, MoayyediP (2007) Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 102: 2047–56; quiz 2057.

6. KwokCS, ArthurAK, AnibuezeCI, SinghS, CavallazziR, et al. (2012) Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107: 1011–1019.

7. JanarthananS, DitahI, AdlerDG, EhrinpreisMN (2012) Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 107: 1001–1010.

8. LeonardCE, FreemanCP, NewcombCW, ReesePP, HerlimM, et al. (2012) Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 21: 1155–1172.

9. BlankM-L, ParkinL, PaulC, HerbisonP (2014) A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int doi:10.1038/ki.2014.74

10. EomC-S, JeonCY, LimJ-W, ChoE-G, ParkSM, et al. (2011) Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 183: 310–319.

11. MarcuardSP, AlbernazL, KhazaniePG (1994) Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 120: 211–215.

12. YuEW, BauerSR, BainPA, BauerDC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124: 519–526.

13. FamularoG, GasbarroneL, MinisolaG (2013) Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf 1–8.

14. MaJ, FolsomAR, MelnickSL, EckfeldtJH, SharrettAR, et al. (1995) Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J Clin Epidemiol 48: 927–940.

15. SchimatschekHF, RempisR (2001) Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res 14: 283–290.

16. SchlingmannKP, WaldeggerS, KonradM, ChubanovV, GudermannT (2007) TRPM6 and TRPM7–Gatekeepers of human magnesium metabolism. Biochim Biophys Acta 1772: 813–821.

17. WeisingerJR, Bellorin-FontE (1998) Magnesium and phosphorus. Lancet 352: 391–396.

18. EpsteinM, McGrathS, LawF (2006) Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 355: 1834–1836.

19. ArulananthamN, AndersonM (2011) A 63-year-old man with hypomagnesaemia and seizures. Clin Med (Northfield, Il) 11: 591–593.

20. BroerenM, GeerdinkE (2009) Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern 151: 755–756.

21. Fernandez-FernandezF (2010) Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med 68: 329–330.

22. ShabajeeN, LambEJ, SturgessI, SumathipalaRW (2008) Omeprazole and refractory hypomagnesaemia. BMJ 337: a425.

23. CundyT, Dissanayakea (2008) Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf) 69: 338–341.

24. FamularoG, MinisolaG, BraviMC, ColucciP, GasbarroneL (2012) Tetany, hypomagnesemia, and proton-pump inhibitors. Am J Med 125: e7–e8.

25. HoornEJ, van der HoekJ, de Man Ra, KuipersEJ, BolwerkC, et al. (2010) A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 56: 112–116.

26. MackayJD, BladonPT (2010) Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 103: 387–395.

27. HessMW, HoenderopJGJ, BindelsRJM, DrenthJPH (2012) Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 36: 405–413.

28. FurlanettoTW, FaulhaberGAM (2011) Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 171: 1391–1392.

29. MatsuyamaJ, TsujiK, DoyamaH, KimF, TakedaY, et al. (2012) Hypomagnesemia Associated with a Proton Pump Inhibitor. Intern Med 51: 2231–2234.

30. GandhiNY, SharifWK, ChadhaS, ShakherJ (2012) A patient on long-term proton pump inhibitors develops sudden seizures and encephalopathy: an unusual presentation of hypomagnesaemia. Case Rep Gastrointest Med 2012: 632721.

31. DanzigerJ, WilliamJH, ScottDJ, LeeJ, LehmanL, et al. (2013) Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 83: 692–699.

32. GauJ, YangY (2012) Uses of proton pump inhibitors and hypomagnesemia. … drug Saf 553–559.

33. KoulouridisI, AlfayezM, TighiouartH, MadiasNE, KentDM, et al. (2013) Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study. Am J Kidney Dis 62: 730–737.

34. LukCP, ParsonsR, LeeYP, HughesJD (2013) Proton pump inhibitor-associated hypomagnesemia: what do FDA data tell us? Ann Pharmacother 47: 773–780.

35. HuxJE, IvisF, FlintoftV, BicaA (2002) Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25: 512–516.

36. SchultzSE, RothwellDM, ChenZ, TuK (2013) Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic Dis Inj Can 33: 160–166.

37. JuurlinkDN, MhscTG, KoDT, SzmitkoPE, AustinPC, et al. (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 713–718.

38. JuurlinkD, GomesT, LipsombeL, AustinPC, HuxJ, et al. (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339: 1–6.

39. Park-WyllieLY, JuurlinkDN, KoppA, ShahBR, StukelTA, et al. (2006) Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354: 1352–1361.

40. SchneeweissS, SeegerJD, MaclureM, WangPS, AvornJ, et al. (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154: 854–864.

41. RegolistiG, CabassiA, ParentiE, MaggioreU, FiaccadoriE (2010) Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis 56: 168–174.

42. WalderRY, LandauD, MeyerP, ShalevH, TsoliaM, et al. (2002) Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 31: 171–174.

43. ChubanovV, WaldeggerS, Mederos y SchnitzlerM, VitzthumH, SassenMC, et al. (2004) Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proc Natl Acad Sci U S A 101: 2894–2899.

44. LainezS, SchlingmannKP, van der WijstJ, DworniczakB, van ZeelandF, et al. (2013) New TRPM6 missense mutations linked to hypomagnesemia with secondary hypocalcemia. Eur J Hum Genet 1–8.

45. ElinRJ (2010) Assessment of magnesium status for diagnosis and therapy. Magnes Res 23: S194–S1988.